Fuda Cancer Hospital
The cost of Immunotherapy with Keytruda (Pembolizumab) in China typically ranges from $6,200 to $11,500. Final expenses depend on the dosage per cycle, the total number of treatment sessions, and clinic-specific administration fees. In the US, similar procedures cost around $21,500 on average. Patients can achieve savings of approximately 59% by seeking treatment in China. This therapy usually includes the medication, oncologist consultation, and intravenous administration.
Bookimed Expert Insight: China offers some of the lowest global prices for brand-name Keytruda. JCI-accredited facilities like Fuda Cancer Hospital in Guangzhou combine this therapy with specialized minimally invasive techniques. Patients seeking advanced oncology care can find significant value here. The hospital serves over 30,000 international patients and specializes in late-stage cancer. This makes it a strategic choice for high-quality care at a lower entry price.
| China | Turkey | Austria | |
| Immunotherapy with Keytruda (Pembolizumab) | from $6,200 | from $3,300 | from $15,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Immunotherapy with Keytruda (Pembolizumab) upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Immunotherapy with Keytruda (Pembolizumab) and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Immunotherapy with Keytruda (Pembolizumab) journey.
Day 1
Day 2
Day 3
Day 4-5
Day 6
Day 7
Weeks 2-4
Please note that each patient"s experience may vary, and you should always follow the advice of your healthcare provider.
Professor Niu Lizhi is a renowned Chinese cancer doctor, President of Fuda Cancer Hospital, and expert in minimally invasive cryosurgery. He has performed over 10,000 cryosurgeries and 500 NanoKnife procedures, and is the author of over 100 papers in surgical oncology, cryosurgery, and NanoKnife. He is Vice-President of the Asian Society of Cryosurgery and the International Society of Cryosurgery, and a member of the Chinese Medication Association, the China Anti-Cancer Association, the International Hepato-Pancreato-Biliary Association, and the Chinese Society of Integrated Traditional Chinese and Western Medicine.
Keytruda, a form of immune-based therapy, leverages the body's immune system to target and destroy cancer cells using monoclonal antibodies.